AnthrimTM , ElusysTherapeutics Inc.'s fast-tracked anthrax antibody therapeutic has successfully passed its human clinical trial designed to determine its safety and tolerability in healthy volunteers, when administered with or without the antibiotic Ciprofloxacin®.
"The Anthim Phase 1 study, AH-101, has concluded and all subjects have completed the 42 day study. There were no serious adverse events and the drug was well tolerated, showing a favorable safety risk-profile, when used either alone or in combination with Ciprofloxacin."
"The successful completion of this human clinical study is an important milestone for Anthim," commented Elizabeth Posillico, Ph.D., President & CEO of Elusys Therapeutics. "This impressive safety data, combined with its published efficacy data, makes Anthim a valuable anthrax countermeasure for the U.S. Government's Strategic National Stockpile under Project BioShield."
ElusysTherapeutics Inc. is a private biopharmaceutical company focused on the development of targeted anti-infective therapeutics using its proprietary Heteropolymer Antibodies (HP) for the treatment of infectious disease.
Source: PR Newswire
Comment Preview